Trial · NCT04043455
Participant flow48
How many started, completed or left each group, period by period.
1 to 20 of 48
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Main Study Double-Blind Treatment Period | STARTED | Main Study Period: Olorinab 10 mg | 67 | |
| Main Study Double-Blind Treatment Period | STARTED | Main Study Period: Olorinab 25 mg | 67 | |
| Main Study Double-Blind Treatment Period | STARTED | Main Study Period: Olorinab 50 mg | 69 | |
| Main Study Double-Blind Treatment Period | STARTED | Main Study Period: Placebo | 70 | |
| Main Study Double-Blind Treatment Period | STARTED | LTE Period: Olorinab 25 mg | 0 | |
| Main Study Double-Blind Treatment Period | STARTED | LTE Period: Olorinab 50 mg | 0 | |
| Main Study Double-Blind Treatment Period | Received Treatment | Main Study Period: Olorinab 10 mg | 67 | |
| Main Study Double-Blind Treatment Period | Received Treatment | Main Study Period: Olorinab 25 mg | 66 | |
| Main Study Double-Blind Treatment Period | Received Treatment | Main Study Period: Olorinab 50 mg | 69 | |
| Main Study Double-Blind Treatment Period | Received Treatment | Main Study Period: Placebo | 70 | |
| Main Study Double-Blind Treatment Period | Received Treatment | LTE Period: Olorinab 25 mg | 0 | |
| Main Study Double-Blind Treatment Period | Received Treatment | LTE Period: Olorinab 50 mg | 0 | |
| Main Study Double-Blind Treatment Period | COMPLETED | Main Study Period: Olorinab 10 mg | 59 | |
| Main Study Double-Blind Treatment Period | COMPLETED | Main Study Period: Olorinab 25 mg | 53 | |
| Main Study Double-Blind Treatment Period | COMPLETED | Main Study Period: Olorinab 50 mg | 61 | |
| Main Study Double-Blind Treatment Period | COMPLETED | Main Study Period: Placebo | 58 | |
| Main Study Double-Blind Treatment Period | COMPLETED | LTE Period: Olorinab 25 mg | 0 | |
| Main Study Double-Blind Treatment Period | COMPLETED | LTE Period: Olorinab 50 mg | 0 | |
| Main Study Double-Blind Treatment Period | NOT COMPLETED | Main Study Period: Olorinab 10 mg | 8 | |
| Main Study Double-Blind Treatment Period | NOT COMPLETED | Main Study Period: Olorinab 25 mg | 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04043455/flow